Literature DB >> 30663794

"Maximum tolerated dose" vs "fixed low-dose" hydroxyurea for treatment of adults with sickle cell anemia.

Titilola S Akingbola1, Bamidele O Tayo2, Chinedu A Ezekekwu1, Omowunmi Sonubi1, Xu Zhang3, Santosh L Saraf3, Robert Molokie3,4, Lewis L Hsu5, Jin Han6, Richard S Cooper2, Victor R Gordeuk3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30663794      PMCID： PMC6440541          DOI： 10.1002/ajh.25412

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  15 in total

1.  Beneficial Effect of Low Fixed Dose of Hydroxyurea in Vaso-occlusive Crisis and Transfusion Requirements in Adult HbSS Patients: A Prospective Study in a Tertiary Care Center.

Authors:  Sudha Sethy; Tribikram Panda; Rabindra Kumar Jena
Journal:  Indian J Hematol Blood Transfus       Date:  2017-09-04       Impact factor: 0.900

Review 2.  Hydroxyurea for the treatment of sickle cell anemia.

Authors:  Orah S Platt
Journal:  N Engl J Med       Date:  2008-03-27       Impact factor: 91.245

3.  Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea.

Authors:  M H Steinberg; Z H Lu; F B Barton; M L Terrin; S Charache; G J Dover
Journal:  Blood       Date:  1997-02-01       Impact factor: 22.113

4.  Proportion of adults with sickle cell anemia and pain crises receiving hydroxyurea.

Authors:  Nicolas Stettler; Colleen M McKiernan; Court Q Melin; Oluwakayode O Adejoro; Nancy B Walczak
Journal:  JAMA       Date:  2015-04-28       Impact factor: 56.272

5.  Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research.

Authors:  Patrick T McGann; Arielle G Hernandez; Russell E Ware
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

6.  Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Authors:  S Charache; F B Barton; R D Moore; M L Terrin; M H Steinberg; G J Dover; S K Ballas; R P McMahon; O Castro; E P Orringer
Journal:  Medicine (Baltimore)       Date:  1996-11       Impact factor: 1.889

7.  Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities.

Authors:  Amanda M Brandow; Julie A Panepinto
Journal:  Expert Rev Hematol       Date:  2010-06       Impact factor: 2.929

8.  Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Authors:  S Charache; M L Terrin; R D Moore; G J Dover; F B Barton; S V Eckert; R P McMahon; D R Bonds
Journal:  N Engl J Med       Date:  1995-05-18       Impact factor: 91.245

9.  Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia.

Authors:  S Charache; G J Dover; R D Moore; S Eckert; S K Ballas; M Koshy; P F Milner; E P Orringer; G Phillips; O S Platt
Journal:  Blood       Date:  1992-05-15       Impact factor: 22.113

10.  Fixed Low-Dose Hydroxyurea for the Treatment of Adults with Sickle Cell Anemia in Nigeria.

Authors:  Bamidele O Tayo; Titilola S Akingbola; Santosh L Saraf; Binal N Shah; Chinedu A Ezekekwu; Omowunmi Sonubi; Lewis L Hsu; Richard S Cooper; Victor R Gordeuk
Journal:  Am J Hematol       Date:  2018-05-14       Impact factor: 10.047
View more
  2 in total

1.  A meta-analysis of toxicities related to hydroxycarbamide dosing strategies.

Authors:  Joacy G Mathias; Vikki G Nolan; Meghan Meadows-Taylor; L Ashley Robinson; Kristen E Howell; James G Gurney; Jane S Hankins; Winfred C Wang; Jeremie H Estepp; Matthew P Smeltzer
Journal:  EJHaem       Date:  2020-04-26

2.  Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic.

Authors:  Michael R DeBaun
Journal:  Blood       Date:  2020-05-28       Impact factor: 22.113
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.